Register | Forgot password?
Switch to Arabic
Friday, November 27 - 2009

Eastern Biotech announces Panel of Cancer Test available for men and women in Dubai

  • United Arab Emirates: Sunday, September 30 - 2007 at 11:29
  • PRESS RELEASE

In Dubai, Dubiotech based company Eastern Biotech & Life Sciences proudly announce Panel of cancer safe test time in Middle East.

Article continues below
 
Panel of Cancersafe test are really a fantastic tumor marker based test separately for Men and Women. Pankaj Sohaney, Manager marketing and Business Development said few laboratory and hospitals are performing individual markers test but its very innovative and novel product in terms of complete panel of cancer detection. One can know in very early stage for detection of cancer.

Dr. Sanjida Ahmed, Director of Research said now a days there is enough awareness among the people that Early detection of cancer is the only solution for cancer detection. Panel of cancer detection will diagnose gene mutation in early stage before it appears physically. It will help to reduce the number of cancer patients in future.

What is Cancersafe test?


It is a highly sophisticated blood test to detect early cancer. Tumor markers have long been used, either to screen for cancers or to monitor cancer treatments, to track and screen for recurrences. Cancersafe test uses a panel of 10/11 tumor markers (10 for women, 11 for men). Tumor markers are molecules appearing in the blood in relation to development of some of the most important cancers. Measurement or identification of tumor markers is useful, because it can detect substances in the blood in early stages, a signal that further medical attention is needed.

Cancersafe test can also be useful in follow-up if you are being treated for the illness. Variations of the tumor markers can be followed by regular tests. Slight to moderate increase may occur 6-12 months before clinical signs of relapse.

Who would perform the test?


Everybody, especially over 40, also young women, caring about breast and ovary. Perform it once a year, or more if required, building your baseline and data for future: your report (since handling all results) will include graphs, demonstrating the evolution of the 10 (or 11) tumor markers: any abnormal increases would be an indication for medical consultation and further investigation.

How to collect the samples?


A normal blood sample from the arm is all that is required. It is very convenient, non-invasive and easy to obtain.

How long?


Result and report is delivered, with comments (from 4 specialists), only two days after your serum specimen reaches the laboratory.

Tests options


• Panel for Women
• Panel for Men

Panel for Women


Everybody, specially over 40, even the young women, caring about breast and ovary should perform this test once a year. The result includes graphs demonstrating the evolution of the following tumor markers. This evolution should be highly considered for treatment and prognosis if the possibility of developing cancer is observed. CEA, CA15-3, CA19-9, CA125, CA72-4, AFP, BHCG, B2M, NSE, CYFRA21-1

Panel for Men


All men, over 40, should perform it once a year, or more if required. This panel covers a wide range of cancers which are common in men. The evolution of the following tumor markers are demonstrated to screen for developing cancers in men. CEA, CA19-9, CA125, CA72-4, PSA+ FPSA, AFP, BHCG, B2M, NSE, CYFRA 21-1
Also consider reading:
Log in to request more information from Eastern Biotech

Notes and media contacts

Pankaj Sohaney
Manager-Marketing & Business Development
Eastern Biotech & Life Sciences FZ-LLC
Dubai Media City
PO Box 212671
Dubai, UAE
tel: 97143692061
fax: 97143631923
mobile: 050-2830422

Disclaimer:

Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com

Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.

For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions